Hvivo
HVO · AIM · Health Care · mcap £41m · 5.8p
hVIVO runs human challenge trials, in which volunteers are deliberately infected with viruses such as flu and RSV in quarantine units to test vaccines and antivirals for pharma and biotech clients. It also offers laboratory services, early-phase clinical units in Germany and bio-storage.
| Target | Promise | Said | Status |
|---|---|---|---|
| 2024 | |||
| H1 2024 | Complete GMP-compliant virus manufacturing in H1 2024 | 13 Dec 2023 | ⏱ Overdue – no update |
|
Status so far
The deadline has passed; no announcement since says whether it was met. We check again as new reports come in. |
|||
| 2025 | |||
| mid-2025 | Conduct multiple Omicron human challenge trials from mid-2025 | 3 Jun 2024 | ⏱ Overdue – no update |
|
Status so far
The deadline has passed; no announcement since says whether it was met. We check again as new reports come in. |
|||